plozalizumab (TAK-202)

News alerts, weekly reports and conference planners

Company:

Takeda

Drug class:

CCR2 receptor inhibitor

Related drugs:

‹

PF-04136309 (0)

›

15d

Population-Based Modeling to Predict Human PK/PD of TAK-500, an Anti-CCR2 Antibody-Drug Conjugate for First-in-Human Study in Cancer Patients. (PubMed, Clin Transl Sci)

TAK-500 is a novel immune cell-directed antibody-drug conjugate (iADC) composed of TAK-202, an anti-CCR2 monoclonal antibody, conjugated to the STING agonist dazostinag (TAK-676), and is designed to stimulate antitumor immunity by reprogramming CCR2-positive monocytes. These findings demonstrate the feasibility of predicting TAK-500 PK and RO in humans by integrating preclinical and parental antibody clinical data, providing a quantitative framework for first-in-human dose selection of immune cell-directed ADCs. Trial Registration: Clinical trials: NCT04420884, NCT04879849.

15 days ago

P1 data • PK/PD data • Journal • First-in-human

CCR2 (C-C Motif Chemokine Receptor 2)

plozalizumab plevistinag (TAK-500) • dazostinag (TAK-676) • plozalizumab (TAK-202)

2years

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma (clinicaltrials.gov)

P1, N=22, Terminated, Millennium Pharmaceuticals, Inc. | Phase classification: P1b --> P1

2 years ago

Phase classification • Combination therapy • Checkpoint inhibition • Metastases

BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)

BRAF mutation • NRAS mutation • BRAF V600

Opdivo (nivolumab) • Yervoy (ipilimumab) • Ojemda (tovorafenib) • Entyvio (vedolizumab) • plozalizumab (TAK-202)

over2years

A Systems Biology Approach for Investigating Significant Biomarkers and Drug Targets Common Among Patients with Gonorrhea, Chlamydia, and Prostate Cancer: A Pilot Study. (PubMed, Bioinform Biol Insights)

Three potential therapeutic compounds namely INCB3284, CCX915, and MLN-1202 were found to interact with up-regulated protein C-C chemokine receptor type 2 (CCR2) in protein-drug interaction analysis. The proposed biomarkers and therapeutic potential molecules could be investigated for potential pharmacological targets and activity in the fight against in patients with gonorrhea, chlamydia, and prostate cancer.

over 2 years ago

Journal

SLFN11 (Schlafen Family Member 11) • GATA6 (GATA Binding Protein 6) • APP (Amyloid Beta Precursor Protein) • KMT2B (Lysine Methyltransferase 2B) • MIR7 (MicroRNA 7) • CCR2 (C-C Motif Chemokine Receptor 2) • HIVEP1 (HIVEP Zinc Finger 1) • SH3BGRL (SH3 Domain Binding Glutamate Rich Protein Like) • DERL1 (Derlin 1) • MARCKS (Myristoylated Alanine Rich Protein Kinase C Substrate) • PRNP (Prion Protein) • PTGS1 (Prostaglandin-Endoperoxide Synthase 1) • SLC40A1 (Solute Carrier Family 40 Member 1)

plozalizumab (TAK-202)